Post by Future Market Insights, Inc.

Investor conversations around GLP-1 drugs are moving beyond hype. A recent Seeking Alpha analysis on Novo Nordisk used Future Market Insights, Inc. estimate that the combined obesity-diabetes drugs market could grow from USD 59.9 billion in 2025 to USD 103.3 billion by 2035, reflecting a CAGR of 5.6%. For pharma companies, the question is not only whether GLP-1 demand is strong today. The deeper question is whether pricing pressure and long-term chronic-care adoption can expand the total addressable market over the next decade. The GLP-1 market will not move in a straight line. Margins may compress. Competition will rise. Policy pressure will remain. But the category is already changing how investors think about obesity, pharma distribution, and chronic-care economics. https://lnkd.in/g45kcchk